Literature DB >> 11954045

Age differences in phosphodiesterase type-IV and its functional response to dopamine D1 receptor modulation in the living brain: a PET study in conscious monkeys.

Norihiro Harada1, Shingo Nishiyama, Hiroyuki Ohba, Kengo Sato, Takeharu Kakiuchi, Hideo Tsukada.   

Abstract

The present study demonstrated the age-related changes in the striatal dopamine D1 receptor binding and its related cAMP second-messenger system in the living brains of conscious young (6.4 +/- 1.8 years old) and aged (19.5 +/- 3.3 years old) monkeys (Macaca mulatta) using positron emission tomography (PET). For quantitative analysis of D1 receptors, [11C]SCH23390 was used and phosphodiesterase type-IV (PDE-IV) activity, as an index of cAMP system, was estimated by two scans with R- and S-[11C]rolipram. Significant age-related decreases in D1 receptor binding were observed in the striatum and frontal cortex. Analysis of uptake of R- and S-[11C]rolipram indicated age-related decreases in PDE-IV activity showing 22.0 and 25.2% decreases in the striatum and frontal cortex, respectively, while no significant changes were observed in the cerebellum. With systemic preadministration of the dopamine D1 receptor antagonist SCH23390 (0.2, 0.6, and 2 mg/kg), the PDE-IV activities in the striatum and frontal cortex were dose-dependently suppressed in both age groups. However, the degree of suppression by SCH23390 was more marked in young than in aged monkeys. These results demonstrate that the striatal cAMP second-messenger system activity as well as its functional response to dopamine D1 antagonist showed age-related impairment in the brain. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11954045     DOI: 10.1002/syn.10067

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  Analysis of (R)- and (S)-[(11)C]rolipram kinetics in canine myocardium for the evaluation of phosphodiesterase-4 with PET.

Authors:  Mireille Lortie; Jean N DaSilva; Miran Kenk; Stephanie Thorn; Darryl Davis; David Birnie; Rob S B Beanlands; Robert A deKemp
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

2.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 3.  Senescent-induced dysregulation of cAMP/CREB signaling and correlations with cognitive decline.

Authors:  Rolf T Hansen; Han-Ting Zhang
Journal:  Brain Res       Date:  2013-04-25       Impact factor: 3.252

Review 4.  Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.

Authors:  Michy P Kelly
Journal:  Cell Signal       Date:  2017-11-23       Impact factor: 4.315

5.  Effects of cAMP-dependent protein kinase activator and inhibitor on in vivo rolipram binding to phosphodiesterase 4 in conscious rats.

Authors:  Tetsuji Itoh; Kohji Abe; Jinsoo Hong; Osamu Inoue; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  Synapse       Date:  2010-02       Impact factor: 2.562

6.  Transient calcium and dopamine increase PKA activity and DARPP-32 phosphorylation.

Authors:  Maria Lindskog; MyungSook Kim; Martin A Wikström; Kim T Blackwell; Jeanette Hellgren Kotaleski
Journal:  PLoS Comput Biol       Date:  2006-09-08       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.